Site Editor

Thomas Flaig, MD


Matt D. Galsky, MD, on Practical Clinical Implications of Using Atezolizumab, Platinum, and Gemcitabine to Treat Urothelial Carcinoma

Posted: Wednesday, March 8, 2023

Matt D. Galsky, MD, of the Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, discusses what the new findings on atezolizumab, platinum, and gemcitabine could mean for patients with previously untreated locally advanced or metastatic urothelial carcinoma. The results he reports are final overall survival rates from the phase III IMvigor130 study.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.